Cargando…
Chronic Pruritus Responding to Dupilumab—A Case Series
Background: Chronic pruritus is defined as itch lasting for greater than six weeks. Pruritus is a burdensome manifestation of several internal and external disease states with a significant impact on quality of life. Dupilumab has shown promise in treating a number of conditions including atopic der...
Autores principales: | Zhai, Lisa L., Savage, Kevin T., Qiu, Connie C., Jin, Annie, Valdes-Rodriguez, Rodrigo, Mollanazar, Nicholas K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789555/ https://www.ncbi.nlm.nih.gov/pubmed/31261951 http://dx.doi.org/10.3390/medicines6030072 |
Ejemplares similares
-
Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia
por: Jin, Annie, et al.
Publicado: (2019) -
Upadacitinib as a treatment for chronic pruritus secondary to polycythemia vera after failure with dupilumab
por: Wachuku, Christopher I., et al.
Publicado: (2023) -
Refractory pruritus responds to dupilumab in a patient with TTC7A mutation
por: Alipour Tehrany, Yassaman, et al.
Publicado: (2020) -
Dupilumab for cancer-associated refractory pruritus
por: Talmon, Aviv, et al.
Publicado: (2023) -
Recalcitrant anal and genital pruritus treated with dupilumab()()()()
por: Yang, E.J., et al.
Publicado: (2018)